A review of liver function tests during treatment with atypical antipsychotic drugs: A chart review study

Objective: Atypical antipsychotic drugs commonly cause asymptomatic increase in the liver enzymes and serum bilirubin levels. However they rarely may induce a serious hepatic toxicity. In this article we aimed to evaluate the effect of atypical antipsychotic drugs namely olanzapine, risperidone and quetiapine on the hepatic enzymes and serum bilirubin levels in psychiatric patients. Method: Chart reviews of 312 patient followed-up at Psychiatry Department of Zonguldak Karaelmas University Hospital were examined in detail. The patients whose baseline and follow-up liver function tests including alanine aminotransfeaminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline phosphotase (ALP) and serum bilirubin that were measured before and within the treatment period of first and sixth months were enrolled. Forty eight males and 62 females whose ages ranging from 12 to 65 years were eligible for this study (no pregnant case was present). Results: The repartition according to treatment is as follows: olanzapine (n = 33), risperidone (n = 29), and quetiapine (n = 48). Two of the 110 patients (1.8%) presented with increased AST levels of up to 4 fold and ALT of thrice the basal level and needed to stop treatment (AST increase in one female with olanzapine 20 mg/day; ALT increase in one male with olanzapine 30 mg/day). Thirty of the 110 patients (27.2%) showed asymptomatic increases in ALT, AST, GGT and serum bilirubin levels in the first month of the study. After 6 months of the treatment, abnormalities in the liver function tests were observed in 25 patients (22.7%). Conclusion: These results were in accordance with previous studies that asymptomatic increase of liver enzymes are common but significant liver enzyme elevations are rare during atypical antipsychotic treatment. We suggest that obtaining baseline liver enzyme tests before atypical antipsychotic therapy and monitoring regularly specifically in patients with risk factors for liver damage during therapy. © 2007 Elsevier Inc. All rights reserved.

Yazar Atasoy N.
Erdogan A.
Yalug I.
Ozturk U.
Konuk N.
Atik L.
Ustundag Y.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/4048
Tek Biçim Adres 10.1016/j.pnpbp.2007.05.005
Konu Başlıkları Atypical antipsychotic
Hepatotoxicity
Liver enzymes
Olanzapine
Quetiapine
Risperidone
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı Progress in Neuro-Psychopharmacology and Biological Psychiatry
Dergi Cilt Bilgisi 31
Dergi Sayısı 6
Sayfalar 1255 - 1260
Yayın Yılı 2007
Eser Adı
[dc.title]
A review of liver function tests during treatment with atypical antipsychotic drugs: A chart review study
Yazar
[dc.contributor.author]
Atasoy N.
Yazar
[dc.contributor.author]
Erdogan A.
Yazar
[dc.contributor.author]
Yalug I.
Yazar
[dc.contributor.author]
Ozturk U.
Yazar
[dc.contributor.author]
Konuk N.
Yazar
[dc.contributor.author]
Atik L.
Yazar
[dc.contributor.author]
Ustundag Y.
Yayın Yılı
[dc.date.issued]
2007
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Objective: Atypical antipsychotic drugs commonly cause asymptomatic increase in the liver enzymes and serum bilirubin levels. However they rarely may induce a serious hepatic toxicity. In this article we aimed to evaluate the effect of atypical antipsychotic drugs namely olanzapine, risperidone and quetiapine on the hepatic enzymes and serum bilirubin levels in psychiatric patients. Method: Chart reviews of 312 patient followed-up at Psychiatry Department of Zonguldak Karaelmas University Hospital were examined in detail. The patients whose baseline and follow-up liver function tests including alanine aminotransfeaminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline phosphotase (ALP) and serum bilirubin that were measured before and within the treatment period of first and sixth months were enrolled. Forty eight males and 62 females whose ages ranging from 12 to 65 years were eligible for this study (no pregnant case was present). Results: The repartition according to treatment is as follows: olanzapine (n = 33), risperidone (n = 29), and quetiapine (n = 48). Two of the 110 patients (1.8%) presented with increased AST levels of up to 4 fold and ALT of thrice the basal level and needed to stop treatment (AST increase in one female with olanzapine 20 mg/day; ALT increase in one male with olanzapine 30 mg/day). Thirty of the 110 patients (27.2%) showed asymptomatic increases in ALT, AST, GGT and serum bilirubin levels in the first month of the study. After 6 months of the treatment, abnormalities in the liver function tests were observed in 25 patients (22.7%). Conclusion: These results were in accordance with previous studies that asymptomatic increase of liver enzymes are common but significant liver enzyme elevations are rare during atypical antipsychotic treatment. We suggest that obtaining baseline liver enzyme tests before atypical antipsychotic therapy and monitoring regularly specifically in patients with risk factors for liver damage during therapy. © 2007 Elsevier Inc. All rights reserved.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Atypical antipsychotic
Konu Başlıkları
[dc.subject]
Hepatotoxicity
Konu Başlıkları
[dc.subject]
Liver enzymes
Konu Başlıkları
[dc.subject]
Olanzapine
Konu Başlıkları
[dc.subject]
Quetiapine
Konu Başlıkları
[dc.subject]
Risperidone
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0278-5846
İlk Sayfa Sayısı
[dc.identifier.startpage]
1255
Son Sayfa Sayısı
[dc.identifier.endpage]
1260
Dergi Adı
[dc.relation.journal]
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Dergi Sayısı
[dc.identifier.issue]
6
Dergi Cilt Bilgisi
[dc.identifier.volume]
31
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1016/j.pnpbp.2007.05.005
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/4048
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
11
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
19 Şubat 2024 20:38
Google Kontrol
Tıklayınız
patients treatment increase antipsychotic bilirubin levels olanzapine atypical enzymes asymptomatic risperidone enzyme quetiapine baseline during function therapy hepatic before 20 mg/day 30 mg/day) female Thirty thrice needed increased presented Objective showed factors suggest obtaining monitoring regularly specifically
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms